Skip to content
PeptideAgent

Selank regulatory status

Current status of Selank in the United States: Removed from Category 2 (Apr 2026). In sport: WADA status unclear. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What is the current status of Selank?

Regulatory: Removed from Category 2 (Apr 2026)WADA: WADA status unclearVerified: Verified Sep 22, 2026
FDA and compounding
Selank was placed on the FDA 503A Category 2 list (substances with significant safety risks) in 2023. The FDA Category 2 page current as of April 22, 2026 now lists selank acetate under bulk drug substances nominated but withdrawn, so it is no longer in Category 2, but it is not on the 503A bulks list and was not among the peptides the Pharmacy Compounding Advisory Committee recommended on July 23 to 24, 2026. With no active nomination and no listing, a 503A pharmacy has no federal basis to compound it from bulk, and state boards cannot authorize what federal law does not. It is not an FDA approved drug and is not eligible for 503B outsourcing. It is a registered prescription drug in Russia.
WADA
WADA status unclear
Access path
  1. Selank is off Category 2 but not on the 503A bulks list, so a 503A pharmacy has no federal basis to compound it from bulk.
  2. Not available as an FDA approved product; registered prescription drug in Russia.
  3. Products labeled research use only are not lawful for human use and are not verified for purity.

Full Selank page: evidence, dosing in the literature, and sources

Is selank FDA approved?

No. Selank is not an FDA approved drug, although it is a registered prescription drug in Russia. Unlike semax, it was not among the peptides the Pharmacy Compounding Advisory Committee recommended for the 503A bulks list in July 2026, so no U.S. approval or compounding listing is pending. [1] [2]

What is the FDA status of selank in 2026?

Removed from Category 2, with no path forward. FDA placed selank on the 503A Category 2 list in 2023, and its Category 2 page (current as of April 22, 2026) now lists selank acetate as nominated but withdrawn. Withdrawal is not approval: selank is not on the 503A bulks list and has no active nomination, so a 503A pharmacy has no federal basis to compound it, and it is not eligible for 503B outsourcing. [2] [3]

Is selank legal in the US?

There is no lawful U.S. source of selank for human use. It is not FDA approved, it cannot lawfully be compounded from bulk, and state boards cannot authorize what federal law does not. Products labeled research use only are not lawful for human use. [2] [3]

Is selank banned by WADA?

Unclear. Selank is not named on the WADA Prohibited List, and because it is an approved drug in Russia it does not automatically fall under section S0 for non-approved substances. Athletes should confirm with their anti-doping organization before use. [4]

How has the status of Selank changed over time?

  1. FDA

    FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2

    FDA's Category 2 page, revised in April 2026 and current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. A withdrawn substance is no longer in 503A Category 2, but withdrawal is not an approval and does not place a substance on the 503A bulks list; a 503A pharmacy still needs a listing before it may compound it. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.

    Regulatory: Removed from Category 2 (Apr 2026)Source: FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B Category 2 lists and withdrawn nominations, content current as of April 22, 2026)
  2. FDA

    FDA places a batch of nominated peptides in 503A Category 2

    In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.

    Regulatory: Not eligible for compoundingSource: FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B Category 2 lists and withdrawn nominations, content current as of April 22, 2026)

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for Selank and the source of each dated event.

  1. [1]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  2. [2]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  3. [3]FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (503A Category 2 list and nominated but withdrawn substances, current as of April 22, 2026)FDA, 2026
  4. [4]WADA Prohibited ListWADA, 2026

From the blog